Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,498 active trials44 approved drugs143 evidence items
- NCIt
- C164141
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,916 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (758)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04958473 | A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer(SAARCC) | unknown | Phase 2 | 40 | Tianjin Medical University Second HospitalOTHER | 1 | Jul 12, 2021 | clinicaltrials |
| NCT02785250 | Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 85 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 |
| clinicaltrials |
| NCT04909775 | Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04846842 | A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | unknown | Phase 2 | 46 | Lee's Pharmaceutical LimitedINDUSTRY | 0 | Apr 19, 2021 | clinicaltrials |
| NCT04839055 | The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC(CoA-CRPC) | unknown | Phase 1 / Phase 2 | 50 | Jiangnan UniversityOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT04068974 | Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer | unknown | Phase 2 | 28 | Peking Union Medical College HospitalOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT04789941 | How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix | unknown | Phase 2 | 50 | Assiut UniversityOTHER | 0 | Mar 10, 2021 | clinicaltrials |
| NCT03824691 | hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"(ARCADIA) | unknown | Phase 2 | 122 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT03943602 | Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)(CaboPen) | unknown | Phase 2 | 37 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT04383067 | A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients | unknown | Phase 2 | 20 | Sheba Medical CenterOTHER_GOV | 1 | Feb 11, 2021 | clinicaltrials |
| NCT02822157 | Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer(CLIO) | unknown | Phase 2 | 160 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT04714697 | Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma | unknown | Phase 2 | 201 | Asan Medical CenterOTHER | 1 | Jan 19, 2021 | clinicaltrials |
| NCT04134182 | Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. | unknown | Phase 2 | 8 | Kidney Cancer Research BureauOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT04664244 | Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma | unknown | Phase 2 | 43 | Lei LiOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT04651946 | Cell-free DNA Methylation for Epithelial Ovarian Cancer | unknown | Phase 2 | 400 | Lei LiOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT04376073 | Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer(ANNIE) | unknown | Phase 2 | 40 | Jihong LiuOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT04644432 | Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma(INDIGO) | unknown | Phase 2 | 30 | Herlev and Gentofte HospitalOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT02031328 | Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer(2STAR) | unknown | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT04635956 | Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas | unknown | Phase 2 | 20 | Lei LiOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT04211012 | A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma | unknown | Phase 2 | 30 | Jun GuoOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04586543 | Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma | unknown | Phase 2 | 110 | László MangelOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT03113266 | Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma | unknown | Phase 2 | 370 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04504110 | 68Ga-FAPI-04 and 18F-FDG PET/CT in Patients With Epithelial Ovarian Cancer: Compared With Histological Findings | unknown | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04486937 | SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation(mCRPC) | unknown | Phase 1 / Phase 2 | 90 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jul 27, 2020 | clinicaltrials |
| NCT03506997 | Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer(PERSEUS1) | unknown | Phase 2 | 100 | Institute of Cancer Research, United KingdomOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT03987698 | Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma | unknown | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT02691975 | A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 197 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 13, 2020 | clinicaltrials |
| NCT04146831 | Sintilimab in FH-deficient Renal Cell Carcinoma | unknown | Phase 2 | 37 | West China HospitalOTHER | 0 | May 12, 2020 | clinicaltrials |
| NCT04264936 | A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer | unknown | Phase 1 / Phase 2 | 36 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT04261465 | NUVOLA TRIAL Open-label Multicentre Study(NUVOLA) | unknown | Phase 2 | 35 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04188587 | 177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer | unknown | Phase 2 | 30 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT04148885 | A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 44 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT03592199 | Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib(SuAx) | unknown | Phase 2 | 7 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT01682772 | TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer(TOPARP) | unknown | Phase 2 | 148 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 15, 2019 | clinicaltrials |
| NCT04049344 | Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma | unknown | Phase 2 | 25 | Zhejiang Cancer HospitalOTHER | 1 | Aug 8, 2019 | clinicaltrials |
| NCT04031378 | Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer | unknown | Phase 2 | 100 | Fundacao ChampalimaudOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT03696186 | Selective Treatment According to Molecular Subtype of Prostate Cancer(STAMP) | unknown | Phase 2 | 300 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT03676946 | A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma | unknown | Phase 1 / Phase 2 | 15 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Sep 26, 2018 | clinicaltrials |
| NCT01037049 | Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks | unknown | Phase 2 | 237 | Royal Marsden NHS Foundation TrustOTHER | 4 | Sep 17, 2018 | clinicaltrials |
| NCT03469531 | Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer | unknown | Phase 2 | 100 | Zhujiang HospitalOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT02919371 | Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) | unknown | Phase 1 / Phase 2 | 77 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT02525068 | A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC(RE-AKT) | unknown | Phase 2 | 136 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 8, 2018 | clinicaltrials |
| NCT03341845 | Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC | unknown | Phase 2 | 40 | The Netherlands Cancer InstituteOTHER | 1 | May 21, 2018 | clinicaltrials |
| NCT02879214 | Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer(Side) | unknown | Phase 2 | 50 | Sichuan Provincial People's HospitalOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01890096 | A Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer | unknown | Phase 2 | 174 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT03196388 | Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate Cancer(ENZART) | unknown | Phase 2 | 70 | Fundación Canaria Instituto de Investigación Sanitaria de CanariasOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02072044 | Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy | unknown | Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 29, 2017 | clinicaltrials |
| NCT03209206 | The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence | unknown | Phase 2 | 84 | Seoul National University HospitalOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT03356912 | CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy | unknown | Phase 2 | 220 | Consorzio OncotechOTHER | 1 | Dec 14, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jul 12, 2021source: clinicaltrials